2024年12月16日，生命科学学院刘亮教授团队在《Nucleic Acids Research》期刊上在线发表了题为“DNA target binding-induced pre-crRNA processing in type II and V CRISPR-Cas systems”的研究论文，首次揭示了靶标核酸的结合能够激活CRISPR-Cas系统效应蛋白对pre-crRNA的反式切割活性 ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The legacy of our ancient human relatives, "brain-eating-amoeba" infections, emerging viral threats, the promise and peril of genome editing, and much, much more — in 2024, Live Science covered a ...

Scientists unveiled a new CRISPR system that reversibly "pauses" genes, rather than permanently disabling them. CRISPR innovator Virginijus Šikšnys spoke with Live Science about the future of ...

Widely used as a genome editing tool, the CRISPR-Cas9 system allows researchers to precisely induce frameshift mutations in specific genes or insert foreign nucleic acid sequences into a cell’s DNA.

根据一项在小鼠中的研究披露，一种新的CRISPR-Cas9方法可以靶向针对心脏中某个有害的信号通路，从而可保护小鼠免于缺血/再 ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...

为了解决CRISPR-Cas基因组编辑中的一个根本性局限，研究人员研发了新型的经设计的Cas9变体，后者几乎消除了对一个被称为PAM的原间隔序列相邻基序 ...

The company has also developed an innovative enrichment method for targeted SMRT Sequencing on its PacBio Sequel System. Utilizing the CRISPR-Cas9 system, this approach eliminates the need for PCR ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $39.36, reflecting a +1.84% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.